ArticleObesity surgery2025
Impact of Prophylactic Apixaban for 14 Days After Sleeve Gastrectomy on Thromboembolic Events and Its Side Effects.
Article in Obesity surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A review of the pharmacokinetics, pharmacodynamics, efficacy, and safety of direct oral anticoagulants in patients undergoing bariatric surgery.Research and practice in thrombosis and haemostasis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a significant complication following bariatric surgery, with most events occurring after discharge. While inpatient VTE chemoprophylaxis is well-established, its extension post-discharge remains controversial. Apixaban, an oral direct factor Xa inhibitor, is a potential alternative for this purpose, offering convenience and a favorable safety profile compared to enoxaparin. This study evaluates the efficacy and safety of a 14-day apixaban regimen in preventing VTE after sleeve gastrectomy (SG).
methodsThis retrospective review analyzed 2737 SG patients who received apixaban 2.5 mg twice daily for 14 days post-discharge between January 2018 and September 2024. Demographics, baseline characteristics, and postoperative complications were collected, focusing on VTE and bleeding events. Patients with contraindications to apixaban, therapeutic anticoagulation, or revisional procedures were excluded.
resultsVTE occurred in 0.1% (3/2737) of patients, all presenting as portomesenteric vein thrombosis. The mean time to diagnosis was 18 days. Bleeding complications were observed in 0.4% (11/2,737) of patients, with abdominal bleeding being the most common source. Most bleeding events were managed conservatively, with only two cases requiring invasive interventions. No deaths or cases of deep vein thrombosis (DVT) or pulmonary embolism (PE) were reported.
conclusionsA 14-day apixaban prophylactic regimen after SG demonstrated low rates of VTE and bleeding complications, comparable to longer regimens and enoxaparin in the literature. Apixaban's fixed dosing, oral administration, and safety profile make it a strong candidate for extended VTE prophylaxis in SG patients. Prospective studies are warranted to validate these findings and inform guideline revisions.
Indexed as
Identifiers
40632450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.